187 related articles for article (PubMed ID: 37004887)
21. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
Schröder O; Blumenstein I; Stein J
Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
[TBL] [Abstract][Full Text] [Related]
22. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
23. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Sazonovs A; Kennedy NA; Moutsianas L; Heap GA; Rice DL; Reppell M; Bewshea CM; Chanchlani N; Walker GJ; Perry MH; McDonald TJ; Lees CW; Cummings JRF; Parkes M; Mansfield JC; Irving PM; Barrett JC; McGovern D; Goodhand JR; Anderson CA; Ahmad T;
Gastroenterology; 2020 Jan; 158(1):189-199. PubMed ID: 31600487
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
Ho Lee Y; Gyu Song G
Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
[TBL] [Abstract][Full Text] [Related]
28. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
29. Adalimumab for induction of remission in Crohn's disease.
Abbass M; Cepek J; Parker CE; Nguyen TM; MacDonald JK; Feagan BG; Khanna R; Jairath V
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742665
[TBL] [Abstract][Full Text] [Related]
30. Methotrexate for maintenance of remission in Crohn's disease.
Patel V; Wang Y; MacDonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006884. PubMed ID: 25157445
[TBL] [Abstract][Full Text] [Related]
31. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
32. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
De Gregorio M; Lee T; Krishnaprasad K; Amos G; An YK; Bastian-Jordan M; Begun J; Borok N; Brown DJM; Cheung W; Connor SJ; Gerstenmaier J; Gilbert LE; Gilmore R; Gu B; Kutaiba N; Lee A; Mahy G; Srinivasan A; Thin L; Thompson AJ; Welman CJ; Yong EXZ; De Cruz P; van Langenberg D; Sparrow MP; Ding NS
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1306-1314. PubMed ID: 34389484
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab for maintenance of remission in Crohn's disease.
Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
[TBL] [Abstract][Full Text] [Related]
34. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.
Plevris N; Jenkinson PW; Arnott ID; Jones GR; Lees CW
Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):32-37. PubMed ID: 31567638
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis.
Narula N; Wong ECL; AlRamdan R; Bualbanat H; Marshall JK; Steinhart AH; Greener T; Silverberg MS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2803-2812. PubMed ID: 34020510
[TBL] [Abstract][Full Text] [Related]
36. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
37. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.
Eriksson C; Söderling J; Karlqvist S; Bröms G; Everhov ÅH; Bergemalm D; Ludvigsson JF; ; Olén O; Halfvarson J
Dig Dis Sci; 2023 Jul; 68(7):3119-3128. PubMed ID: 36929241
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease.
Hradsky O; Kazeka D; Copova I; Lerchova T; Mitrova K; Pospisilova K; Sulovcova M; Zarubova K; Bronsky J
Eur J Pediatr; 2021 Sep; 180(9):3001-3008. PubMed ID: 33876264
[TBL] [Abstract][Full Text] [Related]
39. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
40. Natalizumab for induction of remission in Crohn's disease.
Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]